Form 4: CRISPR Therapeutics Executive Granted Stock Options and Restricted Stock Units

James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, received stock options and restricted stock units on March 14, 2025.

Summary

• James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, was granted stock options and restricted stock units on March 14, 2025.
• The stock option grants him the right to buy 36,666 common shares at a price of $42.12 per share.
• These options vest in 48 equal monthly installments starting April 14, 2025.
• Kasinger also received 27,500 restricted stock units, each representing a contingent right to receive one share of CRSP Common Shares.
• One quarter of the restricted stock units will vest annually on March 14, from 2026 to 2029.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting the grant of stock options and restricted stock units. It's a standard practice, so neither particularly positive nor negative.

Positives

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedules incentivize long-term performance and retention.

Future Outlook

This document does not contain forward-looking statements about the company's future performance, only details of stock and RSU grants.

Industry Context

Stock option and RSU grants are a common practice in the biotechnology industry to attract, retain, and incentivize key executives. The size and vesting schedule of these grants are generally aligned with industry standards for companies of similar size and stage of development.

Comparison to Industry Standards

• Comparing CRISPR Therapeutics' executive compensation practices to those of similar gene-editing companies like Intellia Therapeutics (NTLA) and Editas Medicine (EDIT) would provide a more comprehensive understanding of whether these grants are in line with industry norms.
• A review of proxy statements and Form 4 filings for these companies would reveal the typical size and vesting schedules of equity grants for executives in similar roles.
• For example, similar grants at Intellia and Editas often have similar vesting schedules, with options vesting over 4 years and RSUs vesting over 3-4 years.

Stakeholder Impact

• The grants dilute existing shareholders' equity to a small degree.
• The grants incentivize the executive to increase shareholder value over the long term.

Key Dates